Recent Updates
Recently added Catalysts

NNC9836-0001

Phase 1

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |Novo Nordisk A/S|Trials Updated: Oct 26, 2026

NNC9836-0001 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment121

FDA Designations

No designations recorded

NNC9836-0001 clinical trials

NNC9836-0001 · 1 trial · 1 indication

Phase 1 1
NCT07896109A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesDiabetes Mellitus, Type 2
NOT YET_RECRUITING121 Analytics
PHASE1NOT YET_RECRUITING
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
NCT07896109121
Unlock trial analytics

Study Endpoints

Primary Endpoints

Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)
From dosing (day 1) until week 26

Measured as events.

Multiple ascending dose (MAD): Number of TEAEs
From dosing (day 1) to week 34

Measured as events.

Secondary Endpoints

SAD: Area under the curve (AUC)0-last, standard deviation (SD): The area under the NNC9836-0001 plasma concentration-time curve from time zero to last measurable concentration after a single dose
From predose day 1 to day 57
SAD:Cmax,SD: The maximum observed NNC9836-0001 plasma concentration after a single dose
From predose day 1 to day 57
MAD: AUC0-28d,MD: The area under the NNC9836-0001 plasma concentration-time curve after multiple doses
From predose day 29 to day 57
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NNC9836-0001EXPERIMENTALParticipants will receive NNC9836-0001 subcutaneously.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo subcutaneously.

Interventions

NameTypeDescription
NNC9836-0001DRUGNNC9836-0001 will be administered subcutaneously.
Placebo (NaCl)DRUGPlacebo (NaCl) will be administered subcutaneously.
Unlock Study Design Details

Eligibility Criteria

Age Range25 Years to 69 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: All participants: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclus...

Countries:Germany
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 26, 2026NCT07896109NEW_TRIAL: changed
LOWOct 26, 2026NCT07896109NEW_TRIAL: changed

Explore more on BiopharmaWatch

Novo Nordisk A/S (NVO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with NCompanies A to ZEvery biotech and pharma company we track